{"id":45478,"date":"2012-05-25T18:28:14","date_gmt":"2012-05-25T18:28:14","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/bayer-healthcare-to-exhibit-innovative-device-technologies-at-2012-snm-annual-meeting.php"},"modified":"2012-05-25T18:28:14","modified_gmt":"2012-05-25T18:28:14","slug":"bayer-healthcare-to-exhibit-innovative-device-technologies-at-2012-snm-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/bayer-healthcare-to-exhibit-innovative-device-technologies-at-2012-snm-annual-meeting.php","title":{"rendered":"Bayer HealthCare to Exhibit Innovative Device Technologies at 2012 SNM Annual Meeting"},"content":{"rendered":"<p><p>    TARRYTOWN, N.Y., May 24, 2012 \/PRNewswire\/ --Bayer    Radiology & Interventional will showcase new device    technologies at the Annual Meeting of the Society of Nuclear    Medicine (SNM) in Miami, June 9-13. The new technology includes    enhancements to the Intego PET Infusion System, as well as    developing platforms for controlled administration of molecular    agents for SPECT and small animal imaging procedures.  <\/p>\n<p>    In PET, the MEDRAD Intego System is a worldwide market leader    and the only FDA cleared system for administration of 18F-FDG    and 18F-NaF. Bayer has continued to innovate and evolve the    Intego platform since its launch in 2008, including adding    software features, expanding compatibility and indications, and    significantly reducing the size of the device. At SNM, Bayer    plans to demonstrate Certegra informatics solutions for Intego,    including wireless integration to HIS\/RIS\/PACS systems which    facilitate downloading the PET modality worklist as an infusion    schedule and sending infusion results to PACS. This new    capability will replace several manual processes, which in turn    will streamline workflow and improve efficiency for PET imaging    clinics.  <\/p>\n<p>    Doug Descalzi, Bayer Sr. Director of Molecular Imaging Devices    said, \"Automated, controlled injection of molecular agents not    only has safety and workflow benefits for staff, it can lead to    improvements in patient care and help clinicians and scientists    unlock the potential of molecular medicine.\"  <\/p>\n<p>    In addition, in a scientific exhibition, the company will    showcase developing technologies for controlled administration    of low energy radiopharmaceuticals and for small animal    molecular imaging. Both platforms demonstrate Bayer innovation    and commitment to controlled administration technology.  <\/p>\n<p>    About Bayer HealthCare  <\/p>\n<p>    The Bayer Group is a global enterprise with core competencies    in the fields of health care, nutrition and high-tech    materials. Bayer HealthCare, a subgroup of Bayer AG with annual    sales of EUR 17.2 billion (2011), is one of the world's    leading, innovative companies in the healthcare and medical    products industry and is based in Leverkusen, Germany. The    company combines the global activities of the Animal Health,    Consumer Care, Medical Care and Pharmaceuticals divisions.    Bayer HealthCare's aim is to discover, develop, manufacture and    market products that will improve human and animal health    worldwide. Bayer HealthCare has a global workforce of 55,700    employees (Dec 31, 2011) and is represented in more than 100    countries. Find more information at <a href=\"http:\/\/www.bayerhealthcare.com\" rel=\"nofollow\">http:\/\/www.bayerhealthcare.com<\/a>.  <\/p>\n<p>    Forward-Looking Statements  <\/p>\n<p>    This release may contain forward-looking statements based on    current assumptions and forecasts made by Bayer Group or    subgroup management. Various known and unknown risks,    uncertainties and other factors could lead to material    differences between the actual future results, financial    situation, development or performance of the company and the    estimates given here. These factors include those discussed in    Bayer's public reports which are available on the Bayer website    at <a href=\"http:\/\/www.bayer.com\" rel=\"nofollow\">http:\/\/www.bayer.com<\/a>. The company assumes no    liability whatsoever to update these forward-looking statements    or to conform them to future events or developments.  <\/p>\n<\/p>\n<p>See original here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bayer-healthcare-exhibit-innovative-device-121700737.html;_ylt=A2KJjbw7z79PpEkAV5z_wgt.\" title=\"Bayer HealthCare to Exhibit Innovative Device Technologies at 2012 SNM Annual Meeting\">Bayer HealthCare to Exhibit Innovative Device Technologies at 2012 SNM Annual Meeting<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> TARRYTOWN, N.Y., May 24, 2012 \/PRNewswire\/ --Bayer Radiology &#038; Interventional will showcase new device technologies at the Annual Meeting of the Society of Nuclear Medicine (SNM) in Miami, June 9-13. The new technology includes enhancements to the Intego PET Infusion System, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/bayer-healthcare-to-exhibit-innovative-device-technologies-at-2012-snm-annual-meeting.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-45478","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45478"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=45478"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=45478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=45478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=45478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}